News

In the study, 144 participants were randomized to receive either the vaccine or placebo to prevent recurrence. The vaccines were initiated within three months of completion of standard

The transaction contemplates the retention of nearly the entirety of the Valeritas workforce. To accomplish the sale in the most efficient manner, Valeritas and its subsidiaries filed voluntary

The gantenerumab arm of phase II/III DIAN-TU-001 study has failed to meet its primary endpoint in people who have an early-onset, inherited form of AD or otherwise known

This round was led by Forbion, with participation from BioMedPartners and founding investor BioGeneration Ventures (BGV). Azafaros was established in 2018 to translate innovative science from Leiden University

“There is an urgent need for new therapeutic options to treat hypoxic-ischemic encephalopathy, a devastating condition that profoundly impacts newborns and their families,” said Ulrich Thienel, M.D., Ph.D.,

Based in Baarn, Covis is involved in the marketing and distribution of branded pharma products for the treatment of chronic and serious medical issues. The company supplies products

This collaboration will focus on the discovery of small molecule drug products to treat broad ranging allergies. Under the terms of the agreement, X-Chem will utilize its DEX

On January 14, 2020, the Company received U.S Food and Drug Administration (FDA) Fast Track Designation for its Oncoprex immunogene therapy in combination with the EGFR tyrosine kinase

Under an exclusive worldwide licence, Aimmune will develop and commercialise the XmAb 7195, an investigational humanised monoclonal antibody. Xencor president and CEO Dr Bassil Dahiyat said: “Aimmune’s focus,